Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Perfluorohexyloctane ophthalmic solution - Novaliq

Drug Profile

Perfluorohexyloctane ophthalmic solution - Novaliq

Alternative Names: NOV 03; Novatears

Latest Information Update: 24 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novaliq
  • Class Eye disorder therapies; Fluorocarbons; Small molecules
  • Mechanism of Action Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dry eyes

Most Recent Events

  • 20 Dec 2019 Bausch Health Companies acquired exclusive license for commercialisation and development from Novaliq for perfluorohexyloctane ophthalmic solution in USA and Canada
  • 20 Dec 2019 Efficacy data from a phase II trial in Dry eyes released by Novaliq
  • 20 Dec 2019 Bausch Health Companies plans an additional phase III studies for Perfluorohexyloctane ophthalmic solution in year 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top